Johnson & Johnson (NYSE:JNJ) Shares Sold by Private Wealth Partners LLC

Private Wealth Partners LLC reduced its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 3.6% in the 1st quarter, HoldingsChannel.com reports. The firm owned 72,557 shares of the company’s stock after selling 2,745 shares during the quarter. Johnson & Johnson comprises approximately 1.2% of Private Wealth Partners LLC’s investment portfolio, making the stock its 28th biggest holding. Private Wealth Partners LLC’s holdings in Johnson & Johnson were worth $12,859,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in JNJ. Norges Bank purchased a new stake in Johnson & Johnson during the fourth quarter valued at about $4,172,929,000. BlackRock Inc. grew its position in Johnson & Johnson by 2.6% during the fourth quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock valued at $34,217,654,000 after acquiring an additional 4,982,885 shares during the period. GQG Partners LLC grew its position in Johnson & Johnson by 1,109.4% during the fourth quarter. GQG Partners LLC now owns 3,954,383 shares of the company’s stock valued at $676,375,000 after acquiring an additional 3,627,424 shares during the period. State Street Corp boosted its position in shares of Johnson & Johnson by 1.8% in the fourth quarter. State Street Corp now owns 144,677,639 shares of the company’s stock worth $24,750,004,000 after buying an additional 2,492,359 shares during the period. Finally, Allspring Global Investments Holdings LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth about $269,447,000. Hedge funds and other institutional investors own 68.78% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the sale, the chief accounting officer now owns 15,473 shares in the company, valued at $2,785,140. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the sale, the chief accounting officer now owns 15,473 shares in the company, valued at $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on JNJ shares. Daiwa Capital Markets started coverage on Johnson & Johnson in a research report on Wednesday, June 22nd. They issued an “outperform” rating for the company. UBS Group decreased their target price on Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Credit Suisse Group upped their target price on Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. Finally, Citigroup cut their price target on Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $189.89.

Johnson & Johnson Trading Up 0.2 %

NYSE:JNJ opened at $174.52 on Friday. The business’s 50-day simple moving average is $175.95 and its 200 day simple moving average is $174.39. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The stock has a market cap of $459.23 billion, a price-to-earnings ratio of 25.40, a price-to-earnings-growth ratio of 3.28 and a beta of 0.63. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. The firm had revenue of $24.02 billion for the quarter, compared to analysts’ expectations of $23.85 billion. During the same quarter in the prior year, the firm posted $2.48 earnings per share. Johnson & Johnson’s revenue for the quarter was up 3.0% compared to the same quarter last year. As a group, sell-side analysts predict that Johnson & Johnson will post 10.05 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be paid a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.59%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s payout ratio is currently 65.79%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.